Company Presentation 3rd Annual CG Cannabis Conference May 2019 - PowerPoint PPT Presentation

OVERVIEW MARKET APPENDIX Leading The Way in Cannabis Derived Medicines with a Seed-to Pharmacy Strategy Company Presentation 3rd Annual CG Cannabis Conference May 2019

Disclaimer OVERVIEW This presentation has been prepared by MGC Pharmaceuticals Limited (“Company”). It does not purport to contain all Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on the information that a prospective investor may require in connection with any potential investment in the Company. certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown You should not treat the contents of this presentation, or any information provided in connection with it, as financial risks. The performance and operations of the Company may be influenced by a number of factors, many of which are advice, financial product advice or advice relating to legal, taxation or investment matters. outside the control of the Company. No representation or warranty, express or implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, either totally or partially or that any particular rate of return will be achieved. agents or employees as to the accuracy, completeness or reasonableness of the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection Given the risks and uncertainties that may cause the Company’s actual future results, performance or achievements to with it, or any omission from this presentation, nor as to the attainability of any estimates, forecasts or projections set be materially different from those expected, planned or intended, recipients should not place undue reliance on these out in this presentation. intentions, expectations, future plans, strategy and prospects. The Company does not warrant or represent that the MARKET actual results, performance or achievements will be as expected, planned or intended. This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs, financial position US disclosure or prospects of the Company. The Company reserves the right to update, amend or supplement the information at any time in its absolute discretion (without incurring any obligation to do so). This document does not constitute any part of any offer to sell, or the solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of any “US person” as defined in Regulation S under the US Neither the Company, nor its related bodies corporate, officers, their advisers, agents and employees accept any Securities Act of 1993 (“Securities Act”). The Company’s shares have not been, and will not be, registered under the responsibility or liability to you or to any other person or entity arising out of this presentation including pursuant to Securities Act or the securities laws of any state or other jurisdiction of the United States, and may not be offered or the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and sold in the United States or to any US person without being so registered or pursuant to an exemption from Investments Commission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding registration including an exemption for qualified institutional buyers. provision of any Australian state or territory legislation (or the law of any similar legislation in any other jurisdiction), APPENDIX or similar provision under any applicable law. Any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded. Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in the Company. Future matters This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of the Company. MGC Pharma | Company Presentation 1

Summary OVERVIEW A European Bio-Pharma Company with a “Seed to Pharmacy” strategy • Cost-effective, high-quality, standardised Cannabinoids derived medicines • Three pharmaceutical products in late stage development • ASX listed since 2016 with a market cap of A$70+ million • Czech Republic: Botanical Research and Development Project MARKET London: European Corporate Headquarters Slovenia: European Operational Base APPENDIX Israel: Scientific Base Malta: Primary Operation Site Australia: Pharma Corporate & Financial Headquarters MGC Pharma | Company Presentation 2

In Numbers OVERVIEW Established leader in the cannabis space 3 3 ver 30 Ove MARKET Oper erati tions Devel eloped ed Years E Exper erien ence Facili ilitie ies products R&D team backed by extensive industry Malta, Slovenia & And pipeline of potential experience Czech Republic products in development APPENDIX Can annabis is f for or EU GMP L Licen ence e Networ ork o k of Med edicinal u use e Approved ed value to e to r reach ver 30 ove EMA and parallel US$ US$58 b bn approvals sought in each Inter ternational geography ahead of in 2028 2028* Partner ers legislation changes MGC Pharma | Company Presentation 3 Source: European Cannabis Report 4 th Edition, Prohibition Partners Report

Global Market OVERVIEW st 2018 Cannabis based medicine Europe expected to be 1 st Estimated Cannabis for Nov ov 1 2018 Medicinal use value sales to increase by largest medical cannabis UK legalised prescription MARKET market. Total healthcare US$58 b $58 billion 182% 2% of medical cannabis spend: €2. €2.3t products in 2028 2016-2020 MEDI DICA CAL NUTRACEUT UTICALS APPENDIX Global CBD nutraceutical Global CBD nutraceutical Health and Wellness Global consumer spending market reached market to grow by on cannabis to total market valued at US$13. $13.7 b 7 billion n 149% 9% US$180 b $180 billion US$32 b $32 billion in 2018 2018-2021 In 2018 by 2022 MGC Pharma | Company Presentation 4 Source: European Cannabis Report 4 th Edition, Prohibition Partners Report

Global Market Potential OVERVIEW • MGC Pharma aims to secure a significant share in the global Cannabis Pharmaceutical Market • MGC Pharma targets large markets, where cannabis for medical uses is likely to have a high degree of success • 3 pharmaceutical products in late stage development MARKET Potential Market for MCG – Global Medicinal Global Pharma tapping in to APPENDIX Cannabis Market Market (2028): both markets (2028): Estimated US$1,567Bn US$154.7Bn value US$58 billion MGC Pharma | Company Presentation 5 Source: Prohibition Partners Reports: the African Cannabis Report, the European Cannabis Report 4th Edition, the LATAM Cannabis Report, the Oceania Cannabis Report Source: The Growing Pharmaceuticals Market: Expert Forecasts and Analysis” by The Business Research Company